- call +1-201-465-4211
- email sales@mrinsights.biz
Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. This growth can spread beyond the lung by the process of metastasis into nearby tissue or other parts of the body. Most cancers that start in the lung, known as primary lung cancers, are carcinomas. The two main types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). The most common symptoms are coughing (including coughing up blood), weight loss, shortness of breath, and chest pains.
Scope of the Report:
This report studies the Lung Cancer market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Lung Cancer market by product type and applications/end industries.
Lung cancer is the most common cause of cancer-related death in men and second most common in women after breast cancer. The most common age at diagnosis is 70 years. Overall, 17.4% of people in the United States diagnosed with lung cancer survive five years after the diagnosis, while outcomes on average are worse in the developing world.
The global Lung Cancer market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Lung Cancer.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Roche
Novartis
Pfizer
Merck
Bristol-Myers Squibb
Eli Lilly And Company
Sanof
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
SCLC Lung Cancer
NSCLC Lung Cancer
Market Segment by Applications, can be divided into
Hospital & Clinics
Cancer Research Centers
Laboratories
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Lung Cancer Market Overview
1.1 Product Overview and Scope of Lung Cancer
1.2 Classification of Lung Cancer by Types
1.2.1 Global Lung Cancer Revenue Comparison by Types (2017-2023)
1.2.2 Global Lung Cancer Revenue Market Share by Types in 2017
1.2.3 SCLC Lung Cancer
1.2.4 NSCLC Lung Cancer
1.3 Global Lung Cancer Market by Application
1.3.1 Global Lung Cancer Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital & Clinics
1.3.3 Cancer Research Centers
1.3.4 Laboratories
1.4 Global Lung Cancer Market by Regions
1.4.1 Global Lung Cancer Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Lung Cancer Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Lung Cancer Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Lung Cancer Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Lung Cancer Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Lung Cancer Status and Prospect (2013-2023)
1.5 Global Market Size of Lung Cancer (2013-2023)
2 Manufacturers Profiles
2.1 Roche
2.1.1 Business Overview
2.1.2 Lung Cancer Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Roche Lung Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novartis
2.2.1 Business Overview
2.2.2 Lung Cancer Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis Lung Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.3 Pfizer
2.3.1 Business Overview
2.3.2 Lung Cancer Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Pfizer Lung Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.4 Merck
2.4.1 Business Overview
2.4.2 Lung Cancer Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Merck Lung Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bristol-Myers Squibb
2.5.1 Business Overview
2.5.2 Lung Cancer Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Bristol-Myers Squibb Lung Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.6 Eli Lilly And Company
2.6.1 Business Overview
2.6.2 Lung Cancer Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Eli Lilly And Company Lung Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.7 Sanof
2.7.1 Business Overview
2.7.2 Lung Cancer Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Sanof Lung Cancer Revenue, Gross Margin and Market Share (2016-2017)
3 Global Lung Cancer Market Competition, by Players
3.1 Global Lung Cancer Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Lung Cancer Players Market Share
3.2.2 Top 10 Lung Cancer Players Market Share
3.3 Market Competition Trend
4 Global Lung Cancer Market Size by Regions
4.1 Global Lung Cancer Revenue and Market Share by Regions
4.2 North America Lung Cancer Revenue and Growth Rate (2013-2018)
4.3 Europe Lung Cancer Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Lung Cancer Revenue and Growth Rate (2013-2018)
4.5 South America Lung Cancer Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Lung Cancer Revenue and Growth Rate (2013-2018)
5 North America Lung Cancer Revenue by Countries
5.1 North America Lung Cancer Revenue by Countries (2013-2018)
5.2 USA Lung Cancer Revenue and Growth Rate (2013-2018)
5.3 Canada Lung Cancer Revenue and Growth Rate (2013-2018)
5.4 Mexico Lung Cancer Revenue and Growth Rate (2013-2018)
6 Europe Lung Cancer Revenue by Countries
6.1 Europe Lung Cancer Revenue by Countries (2013-2018)
6.2 Germany Lung Cancer Revenue and Growth Rate (2013-2018)
6.3 UK Lung Cancer Revenue and Growth Rate (2013-2018)
6.4 France Lung Cancer Revenue and Growth Rate (2013-2018)
6.5 Russia Lung Cancer Revenue and Growth Rate (2013-2018)
6.6 Italy Lung Cancer Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Lung Cancer Revenue by Countries
7.1 Asia-Pacific Lung Cancer Revenue by Countries (2013-2018)
7.2 China Lung Cancer Revenue and Growth Rate (2013-2018)
7.3 Japan Lung Cancer Revenue and Growth Rate (2013-2018)
7.4 Korea Lung Cancer Revenue and Growth Rate (2013-2018)
7.5 India Lung Cancer Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Lung Cancer Revenue and Growth Rate (2013-2018)
8 South America Lung Cancer Revenue by Countries
8.1 South America Lung Cancer Revenue by Countries (2013-2018)
8.2 Brazil Lung Cancer Revenue and Growth Rate (2013-2018)
8.3 Argentina Lung Cancer Revenue and Growth Rate (2013-2018)
8.4 Colombia Lung Cancer Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Lung Cancer by Countries
9.1 Middle East and Africa Lung Cancer Revenue by Countries (2013-2018)
9.2 Saudi Arabia Lung Cancer Revenue and Growth Rate (2013-2018)
9.3 UAE Lung Cancer Revenue and Growth Rate (2013-2018)
9.4 Egypt Lung Cancer Revenue and Growth Rate (2013-2018)
9.5 Nigeria Lung Cancer Revenue and Growth Rate (2013-2018)
9.6 South Africa Lung Cancer Revenue and Growth Rate (2013-2018)
10 Global Lung Cancer Market Segment by Type
10.1 Global Lung Cancer Revenue and Market Share by Type (2013-2018)
10.2 Global Lung Cancer Market Forecast by Type (2018-2023)
10.3 SCLC Lung Cancer Revenue Growth Rate (2013-2023)
10.4 NSCLC Lung Cancer Revenue Growth Rate (2013-2023)
11 Global Lung Cancer Market Segment by Application
11.1 Global Lung Cancer Revenue Market Share by Application (2013-2018)
11.2 Lung Cancer Market Forecast by Application (2018-2023)
11.3 Hospital & Clinics Revenue Growth (2013-2018)
11.4 Cancer Research Centers Revenue Growth (2013-2018)
11.5 Laboratories Revenue Growth (2013-2018)
12 Global Lung Cancer Market Size Forecast (2018-2023)
12.1 Global Lung Cancer Market Size Forecast (2018-2023)
12.2 Global Lung Cancer Market Forecast by Regions (2018-2023)
12.3 North America Lung Cancer Revenue Market Forecast (2018-2023)
12.4 Europe Lung Cancer Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Lung Cancer Revenue Market Forecast (2018-2023)
12.6 South America Lung Cancer Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Lung Cancer Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Lung Cancer Picture
Table Product Specifications of Lung Cancer
Table Global Lung Cancer and Revenue (Million USD) Market Split by Product Type
Figure G
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
